Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Cofoe Medical, indicating a decline in revenue and profit in the latest quarterly report [2][3] - As of July 10, Cofoe Medical's stock closed at 34.68 yuan, with a 3.12% increase, and a rolling PE ratio of 24.01, marking a new low in 66 days [1] - The total market capitalization of Cofoe Medical is 7.251 billion yuan, which is significantly lower than the industry average PE ratio of 51.40 and median of 37.27 [1][3] Group 2 - Cofoe Medical specializes in the research, production, sales, and service of medical devices, with a diverse product range including blood glucose systems, blood pressure monitors, and various medical supplies [2] - The latest quarterly report for Q1 2025 shows that the company achieved an operating revenue of 738 million yuan, a year-on-year decrease of 8.59%, and a net profit of 91.425 million yuan, down 9.68% [2] - The gross profit margin for Cofoe Medical stands at 52.17%, indicating a relatively stable profitability despite the decline in revenue and profit [2]
可孚医疗收盘上涨3.12%，滚动市盈率24.01倍，总市值72.51亿元